<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00278538</url>
  </required_header>
  <id_info>
    <org_study_id>DI SLE.Auto2003</org_study_id>
    <nct_id>NCT00278538</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus</brief_title>
  <official_title>Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus: Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to examine whether treating patients with lupus with high dose&#xD;
      cyclophosphamide together with rATG/rituximab (drugs which reduce the function of the immune&#xD;
      system), followed by return of their previously collected stem cells will result in&#xD;
      improvement in the disease. Stem cells are undeveloped cells that have the capacity to grow&#xD;
      into mature blood cells, which normally circulate in the blood stream. The purpose of the&#xD;
      intense chemotherapy is to destroy the cells in the immune system which may be causing this&#xD;
      disease. The purpose of the stem cell infusion is to produce a normal immune system that will&#xD;
      no longer attack body. The study purpose is to examine whether this treatment will result in&#xD;
      improvement in the lupus disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mobilization Participants will be administered Cyclophosphamide at 2.0 g/m2 in 200 ml of&#xD;
      normal saline (NS) over 1 hour. Hydration with 0.9 NS at approximately 100-250-ml/ hour will&#xD;
      begin 4 hours prior to cyclophosphamide and continued for 24 hours after termination of&#xD;
      cyclophosphamide. Urine output approximately greater than 100 ml/hour should be maintained.&#xD;
&#xD;
      Granulocyte-colony stimulating factor (G-CSF) will be administered subcutaneously at 5-10&#xD;
      mcg/kg/day and will be started 5 days after termination of cyclophosphamide administration.&#xD;
&#xD;
      After the absolute neutrophil count is greater than 1000/ul or after hematological nadir,&#xD;
      leukapheresis using a continuous flow blood cell separator will be initiated. A 10-15 liter&#xD;
      apheresis will be performed unless stopped earlier for clinical judgment of toxicity (e.g.,&#xD;
      numbness, tetany). The G-CSF will continue until apheresis is discontinued. If necessary,&#xD;
      platelets will be transfused to greater than 60,000/ul prior to each apheresis.&#xD;
&#xD;
      Conditioning Regimen Mesna: 50mg/kg/day x 4 days will be given intravenously over 24 hours.&#xD;
&#xD;
      Cyclophosphamide: 50 mg/kg/day x 4 days (the lesser of ideal or actual weight) will be given&#xD;
      intravenously over 1 hour in 250 cc of normal saline on days -5 through -2.&#xD;
&#xD;
      Hydration: approximately 50-200cc/hour in adults should begin 6 hours before cyclophosphamide&#xD;
      and continue until 24 hours after the last cyclophosphamide dose. Hydration rates need to be&#xD;
      individually adjusted by daily weights to maintain dry weight count. Twice daily weights will&#xD;
      be obtained. Warning: Participants with renal insufficiency are prone to volume overload.&#xD;
      Early institution of ultrafiltration or dialysis is recommended.&#xD;
&#xD;
      rATG 0.5mg/kg will be given IV on day -5, 1.0mg/kg will be given on day&#xD;
&#xD;
      -4, 1.5mg/kg will be given IV on days -3, -2, -1 (no dose adjustment). It will be given over&#xD;
      10 hours. Premedicate with Solumedrol 250mg IV, acetaminophen 650mg po qd and diphenhydramine&#xD;
      25mg 30 minutes before infusion.&#xD;
&#xD;
      Rituximab 500mg/day will be given IV on days -6 and +1. At the first dose (D-6), rituximab&#xD;
      infusion will be started at 50mg/h and escalate the infusion rate by 50mg every 30minutes to&#xD;
      a maximum of 400mg/h. Starting the second dose (days -4, -2 and +1). IV infusion will be&#xD;
      started at 100mg/h and escalate the infusion rate 100mg every 30minutes to a maximum of&#xD;
      400mg/h. Premedicate with Solumedrol 250mg IV, acetaminophen 650mg po qd and diphenhydramine&#xD;
      25mg 30 minutes before infusion on days -6 and +1. Premedicate acetaminophen 650mg po qd and&#xD;
      diphenhydramine 25mg 30 minutes before infusion on days -4 and -2.&#xD;
&#xD;
      Stem Cell Reinfusion Previously collected stem cells will be reinfused on day 0 as noted in&#xD;
      Table 4. The stem cells are infused over approximately 20 minutes through the central venous&#xD;
      catheter, such as a peripherally inserted central catheter (PICC line). Following stem cell&#xD;
      reinfusion, routine daily labs will be obtained including complete blood count (CBC),&#xD;
      chemistry panel, and liver function tests. Antibiotics and blood transfusions will be&#xD;
      administered as required by clinical judgment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 23, 2005</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>6 months, then yearly x 5 years after transplant</time_frame>
    <description>The primary efficacy outcome is overall survival.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Hematopoietic Stem Cell Transplant Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Hematopoietic Stem Cell Transplantation: Rituximab, rATG and Cyclophosphamide regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hematopoietic stem cell transplantation</intervention_name>
    <description>Autologous hematopoietic stem cell transplantation</description>
    <arm_group_label>Hematopoietic Stem Cell Transplant Regimen 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 15 to 60 years old&#xD;
&#xD;
          -  Meet at least 4 of 11 American College of Rheumatology (ACR) Classification criteria&#xD;
             for systemic lupus erythematosus (SLE) (see Appendix 16.2)&#xD;
&#xD;
          -  Meet one of following five:&#xD;
&#xD;
               1. For lupus nephritis, participants must fail pulse cyclophosphamide (500 to 1000&#xD;
                  mg/m2 monthly for a minimum of 6 months). Failure is defined as meeting criteria&#xD;
                  to be considered as BILAG renal category A.&#xD;
&#xD;
               2. For visceral organ involvement other than nephritis, participants must be BILAG&#xD;
                  cardiovascular/respiratory category A, vasculitis category A, or neurologic&#xD;
                  category A and must fail at least 3 months of oral or IV cyclophosphamide and be&#xD;
                  corticosteroid dependent. Steroid dependence being defined as at least 3 months&#xD;
                  of steroid therapy and inability to wean corticosteroid to less than 20 mg/day of&#xD;
                  prednisone or equivalent.&#xD;
&#xD;
               3. For cytopenias that are immune mediated, participants must be BILAG hematologic&#xD;
                  category A. Participants must fail corticosteroids (either oral prednisone &gt; 0.5&#xD;
                  mg/kg/day for more than 6 months or pulse methylprednisolone for at least one&#xD;
                  cycle of three days), and at least one of the following: azathioprine at 2&#xD;
                  mg/kg/day for at least 3 months, mycophenolate mofetil 2 grams daily for more&#xD;
                  than 3 months, cyclophosphamide intravenously or orally for at least 3 months, or&#xD;
                  cyclosporine at least 3 mg/kg/day for at least 3 months, danazol for at least 3&#xD;
                  months, or splenectomy.&#xD;
&#xD;
               4. For mucocutaneous disease, participants must meet BILAG mucocutaneous category A,&#xD;
                  be unable to be weaned from prednisone to less than 0.5 mg/kg/day for more than 6&#xD;
                  months and obvious cushingoid habitus, and have received at least one of the&#xD;
                  following: azathioprine at 2 mg/kg/day for at least 3 months, methotrexate at&#xD;
                  15mg/week for at least 3 months, cyclophosphamide intravenously or orally for at&#xD;
                  least 3 months, or cyclosporine at least 3 mg/kg/day for at least 3 months.&#xD;
&#xD;
               5. For arthritis/myositis, participants must meet BILAG musculoskeletal category A,&#xD;
                  be unable to be weaned from prednisone to less than 0.5 mg/kg/day for more than 6&#xD;
                  months and obvious cushingoid habitus, and have received at least one of the&#xD;
                  following: azathioprine at 2 mg/kg/day for at least 3 months, methotrexate at&#xD;
                  15mg/ week for at least 3 months, cyclophosphamide intravenously or orally for at&#xD;
                  least 3 months, or cyclosporine at least 3 mg/kg/day for at least 3 months.&#xD;
&#xD;
          -  Able to give informed consent.&#xD;
&#xD;
          -  If indication for hematopoietic stem cell transplant (HSCT) is nephritis, a renal&#xD;
             biopsy must demonstrate the potential of a reversible (non-fibrotic) component&#xD;
             indicating that if successful the participant would not be likely to be permanently&#xD;
             dialysis-dependent after transplant.&#xD;
&#xD;
          -  Since the BILAG is only one of multiple indices for SLE, patients may also be&#xD;
             candidates if despite prior immune suppression therapy as described above, patients&#xD;
             are still on active immune suppression (more than 10mg a day of prednisone).&#xD;
&#xD;
          -  Patients with SLE whose major manifestation is Antiphospholipid syndrome (APS) may be&#xD;
             candidates without prior immune suppression therapy if they have had a visceral organ&#xD;
             thrombotic or embolic event despite anticoagulation.&#xD;
&#xD;
          -  Patients with SLE whose major manifestation is Antiphospholipid syndrome (APS) may be&#xD;
             candidates without prior immune suppression therapy if they have had a visceral organ&#xD;
             thrombotic or embolic event despite anticoagulation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Ongoing malignancy except localized basal cell or squamous skin cancer. Other&#xD;
             malignancies for which the participant is judged to be cured by local surgical&#xD;
             therapy, such as head and neck cancer, or stage I or II breast cancer will be&#xD;
             considered on an individual basis by the investigators doing the final screening for&#xD;
             participant qualification.&#xD;
&#xD;
          -  Positive pregnancy test, inability or unwillingness to pursue effective means of birth&#xD;
             control, failure to willingly accept or comprehend irreversible sterility as a side&#xD;
             effect of therapy.&#xD;
&#xD;
          -  Psychiatric illness or mental deficiency making compliance with treatment or informed&#xD;
             consent impossible.&#xD;
&#xD;
          -  Diffusing capacity of lung for carbon monoxide (DLCO) &lt; 45% of predicted unless&#xD;
             attributed to active lupus.&#xD;
&#xD;
          -  Resting left ventricular ejection fraction (LVEF) &lt; 40% unless attributed to active&#xD;
             lupus.&#xD;
&#xD;
          -  Known hypersensitivity to E Coli derived proteins.&#xD;
&#xD;
          -  Transaminases greater than 2 times normal unless attributed to active lupus.&#xD;
&#xD;
          -  Positive tuberculosis skin test&#xD;
&#xD;
          -  Any active infection&#xD;
&#xD;
          -  Any co-morbid illness that in the opinion of the investigator would jeopardize the&#xD;
             ability of the subject to tolerate the study.&#xD;
&#xD;
          -  Failure to collect at least 2.0 x 106 cluster of differentiation 34 (CD34+) cells/kg&#xD;
&#xD;
          -  Antinuclear antibody (ANA)-negative&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Burt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University, Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.nature.com/articles/s41409-018-0173-x</url>
    <description>Bone Marrow Transplant</description>
  </link>
  <reference>
    <citation>Burt RK, Han X, Gozdziak P, Yaung K, Morgan A, Clendenan AM, Henry J, Calvario MA, Datta SK, Helenowski I, Schroeder J. Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: effect of conditioning regimen on outcome. Bone Marrow Transplant. 2018 Jun;53(6):692-700. doi: 10.1038/s41409-018-0173-x. Epub 2018 May 31.</citation>
    <PMID>29855561</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 15, 2006</study_first_submitted>
  <study_first_submitted_qc>January 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2006</study_first_posted>
  <results_first_submitted>November 18, 2019</results_first_submitted>
  <results_first_submitted_qc>February 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2020</results_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Richard Burt, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Stem cell, Autoimmune disease, Systemic Lupus Erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 29, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT00278538/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 29, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT00278538/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Autologous hematopoietic stem cell transplantation will be performed&#xD;
Hematopoietic stem cell transplantation: Autologous hematopoietic stem cell transplantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Autologous hematopoietic stem cell transplantation will be performed&#xD;
Hematopoietic stem cell transplantation: Autologous hematopoietic stem cell transplantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" lower_limit="16" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival</title>
        <description>The primary efficacy outcome is overall survival.</description>
        <time_frame>6 months, then yearly x 5 years after transplant</time_frame>
        <population>The # analyzed at 6 mos.- 4 years differs from the overall participant # analyzed because 2 participants were declined HSCT due to comorbidities and 2 died within 6 mos. after HSCT unrelated to the treatment. The # analyzed at 5 years differs from the overall participants analyzed due to an unrelated treatment death at 4 years after HSCT.&#xD;
.</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Autologous hematopoietic stem cell transplantation will be performed&#xD;
Hematopoietic stem cell transplantation: Autologous hematopoietic stem cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>The primary efficacy outcome is overall survival.</description>
          <population>The # analyzed at 6 mos.- 4 years differs from the overall participant # analyzed because 2 participants were declined HSCT due to comorbidities and 2 died within 6 mos. after HSCT unrelated to the treatment. The # analyzed at 5 years differs from the overall participants analyzed due to an unrelated treatment death at 4 years after HSCT.&#xD;
.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Month Post Transplant Survival</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Total Participant Survival</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non Treatment Related Death</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year Post Transplant Survival</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Total Participant Survival</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non Treatment Related Death</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year Post Transplant Survival</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Total Participant Survival</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non Treatment Related Death</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Year Post Transplant Survival</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Total Participant Survival</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non Treatment Related Death</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Year Post Transplant Survival</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Total Participant Survival</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non Treatment Related Death</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Year Post Transplant Survival</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Total Participant Survival</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non Treatment Related Death</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Autologous hematopoietic stem cell transplantation will be performed&#xD;
Hematopoietic stem cell transplantation: Autologous hematopoietic stem cell transplantation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Troponin</sub_title>
                <description>Grade 4 Toxicity During HSCT Hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial Hemorrhage</sub_title>
                <description>Grade 4 Toxicity During HSCT Hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>Grade 4 Toxicity During HSCT Hospitalization</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Grade 3 Toxicity During HSCT Hospitalization</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <description>Grade 3 Toxicity During HSCT Hospitalization</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Grade 3 Toxicity During HSCT Hospitalization</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Elevated Transaminase</sub_title>
                <description>Grade 3 Toxicity During HSCT Hospitalization</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic Fevers</sub_title>
                <description>Grade 3 Toxicity During HSCT Hospitalization</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>Grade 3 Toxicity During HSCT Hospitalization</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>Grade 3 Toxicity During HSCT Hospitalization</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <description>Grade 3 Toxicity During HSCT Hospitalization</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <description>Grade 3 Toxicity During HSCT Hospitalization</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>Grade 3 Toxicity During HSCT Hospitalization</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathleen Quigley</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-8192</phone>
      <email>k-quigley@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

